A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 507 participants.

Also called NCT01456169

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 507 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01456169
  • EudraCT 2011-000220-16
  • WHO UTN U1111-1119-4743
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Bulgaria, Estonia, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, Serbia, Slovakia, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01456169. Randomized; quadruple masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2012-12 (actual). Results posted on 2014-04-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone
Condition
Essential Hypertension
Intervention (Drug)
Azilsartan medoxomil/placebo
Intervention (Drug)
Azilsartan medoxomil - chlorthalidone
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct01456169
Content hash
dcfd894e530ebeb9608c8f7cbb37d10954292f4ff71bdbbca3fc501490736ff1